Neovacs is developing new treatments for autoimmune and inflammatory diseases, using its proprietary technology, known as Kinoids®. These therapeutic vaccines use the patient’s own immune system to generate the production of natural antibodies neutralizing the overproduced cytokines (proteins) responsible for the disease. For example in lupus, the anti-interferon-alpha (IFNα) antibodies generated by IFN Kinoid target IFNα, which is the cytokine involved in lupus disease. Kinoids®are a combination of a targeted cytokine to a carrier protein to make it immunogenic.
WHY SHOULD YOU INVEST IN NEOVACS ?GO TO THE INVESTORS SECTION